

Reference number(s)
1930-A

SPECIALTY GUIDELINE MANAGEMENT

NEUPOGEN (filgrastim) GRANIX (tbo-filgrastim) ZARXIO (filgrastim-sndz) NIVESTYM (filgrastim-aafi)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

Neupogen

1. Patients with Cancer Receiving Myelosuppressive Chemotherapy
Neupogen is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
2. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
Neupogen is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.
3. Patients with Cancer Receiving Bone Marrow Transplant
Neupogen is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, (e.g., febrile neutropenia) in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation.
4. Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy
Neupogen is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
5. Patients With Severe Chronic Neutropenia
Neupogen is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.
6. Patients Acutely Exposed to Myelosuppressive Doses of Radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Reference number(s)
1930-A

Neupogen is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).

Nivestym

1. **Patients with Cancer Receiving Myelosuppressive Chemotherapy**
Nivestym is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
2. **Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy**
Nivestym is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia (AML).
3. **Patients with Cancer Receiving Bone Marrow Transplantation (BMT)**
Nivestym is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, (e.g., febrile neutropenia) in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
4. **Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy**
Nivestym is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
5. **Patients With Severe Chronic Neutropenia**
Nivestym is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.

Granix

Granix is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Zarxio

1. **Patients with Cancer Receiving Myelosuppressive Chemotherapy**
Zarxio is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
2. **Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy**
Zarxio is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia (AML).
3. **Patients with Cancer Undergoing Bone Marrow Transplantation**
Zarxio is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, (e.g., febrile neutropenia) in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
4. **Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy**
Zarxio is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.

Reference number(s)
1930-A

5. Patients With Severe Chronic Neutropenia
Zarxio is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.

B. Compendial Uses (Neupogen/Granix/Zarxio/Nivestym)

1. Treatment of chemotherapy-induced febrile neutropenia in patients with non-myeloid malignancies
2. Prophylaxis for chemotherapy-induced febrile neutropenia in patients with solid tumors
3. Treatment of anemia and neutropenia in patients with myelodysplastic syndromes (MDS)
4. Stem cell transplantation-related indications
5. Agranulocytosis (non-chemotherapy drug induced)
6. Aplastic anemia
7. Neutropenia related to HIV/AIDS
8. Neutropenia related to renal transplantation
9. Acute myeloid leukemia
10. Severe chronic neutropenia (congenital, cyclic, or idiopathic)
11. Hematopoietic Syndrome of Acute Radiation Syndrome
12. Supportive care for neutropenic patients with CAR T-cell-related toxicities
13. Hairy Cell Leukemia
14. Chronic Myeloid Leukemia
15. Glycogen Storage Disease (GSD) Type 1

All other indications are considered experimental/investigational and not medically necessary.

II. REQUIRED DOCUMENTATION

Primary Prophylaxis of Febrile Neutropenia

Documentation must be provided of the member's diagnosis and chemotherapeutic regimen.

III. CRITERIA FOR INITIAL APPROVAL

A. Neutropenia in cancer patients receiving myelosuppressive chemotherapy

Authorization of 6 months may be granted for prevention or treatment of febrile neutropenia when all of the following criteria are met (1, 2, and 3):

1. The requested medication will not be used in combination with other colony stimulating factors within any chemotherapy cycle.
2. The member will not be receiving concurrent chemotherapy and radiation therapy.
3. One of the following criteria is met (i, ii, or iii):
 - i. The requested medication will be used for primary prophylaxis in members with solid tumors or non-myeloid malignancies who have received, are currently receiving, or will be receiving myelosuppressive anti-cancer therapy that is expected to result in 20% or higher incidence of FN (febrile neutropenia) (FN) (See *Appendix A*) OR 10 – 19% risk of FN (See *Appendix B*).
 - ii. The requested medication will be used for secondary prophylaxis in members with solid tumors or non-myeloid malignancies who experienced a febrile neutropenic complication or a dose-limiting neutropenic event (a nadir or day of treatment count impacting the planned dose of

Reference number(s)
1930-A

- chemotherapy) from a prior cycle of similar chemotherapy, with the same dose and schedule planned for the current cycle (for which primary prophylaxis was not received)
- iii. The requested medication will be used for treatment of high risk FN.

B. Other indications

Authorization of 6 months may be granted for members with any of the following indications:

1. Myelodysplastic syndrome (anemia or neutropenia)
2. Stem cell transplantation-related indications
3. Agranulocytosis (non-chemotherapy drug induced)
4. Aplastic anemia
5. Neutropenia related to HIV/AIDS
6. Neutropenia related to renal transplantation
7. Acute myeloid leukemia
8. Severe chronic neutropenia (congenital, cyclic, or idiopathic)
9. Hematopoietic Syndrome of Acute Radiation Syndrome
Treatment for radiation-induced myelosuppression following a radiological/nuclear incident
10. CAR T-cell-related toxicities
Supportive care for neutropenic patients with CAR T-cell-related toxicities
11. Hairy Cell Leukemia
Members with hairy cell leukemia with neutropenic fever following chemotherapy
12. Chronic Myeloid Leukemia
Members with chronic myeloid leukemia (CML) for treatment of persistent neutropenia due to tyrosine kinase inhibitor therapy
13. Glycogen Storage Disease (GSD) Type 1
Individuals with GSD Type 1 for treatment of low neutrophil counts

IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

V. APPENDIX

- A. APPENDIX A: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 20% or Higher*
 1. Acute Lymphoblastic Leukemia:
Select ALL regimens as directed by treatment protocol (see NCCN guidelines ALL)
 2. Bladder Cancer:
 - i. Dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)
 - ii. CBDCa/Pac (carboplatin, paclitaxel)
 3. Bone Cancer:
 - i. VAI (vincristine, doxorubicin or dactinomycin, ifosfamide)
 - ii. VDC-IE (vincristine, doxorubicin or dactinomycin, and cyclophosphamide alternating with ifosfamide and etoposide)
 - iii. Cisplatin/doxorubicin
 - iv. VDC (cyclophosphamide, vincristine, doxorubicin or dactinomycin)

Reference number(s)
1930-A

- v. VIDE (vincristine, ifosfamide, doxorubicin or dactinomycin, etoposide)
- 4. Breast Cancer:
 - i. Docetaxel + trastuzumab
 - ii. Dose-dense AC (doxorubicin, cyclophosphamide) + paclitaxel (or dose dense paclitaxel)
 - iii. TAC (docetaxel, doxorubicin, cyclophosphamide)
 - iv. AT (doxorubicin, docetaxel)
 - v. Doc (docetaxel)
 - vi. TC (docetaxel, cyclophosphamide)
 - vii. TCH (docetaxel, carboplatin, trastuzumab)
- 5. Colorectal Cancer:
FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, irinotecan)
- 6. Esophageal and Gastric Cancers:
Docetaxel/cisplatin/fluorouracil
- 7. Head and Neck Squamous Cell Carcinoma:
TPF (docetaxel, cisplatin, 5-fluorouracil)
- 8. Hodgkin Lymphoma:
 - i. Brentuximab vedotin + AVD (doxorubicin, vinblastine, dacarbazine)
 - ii. Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
- 9. Kidney Cancer:
Doxorubicin/gemcitabine
- 10. Non-Hodgkin's Lymphoma:
 - i. Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
 - ii. ICE (ifosfamide, carboplatin, etoposide)
 - iii. Dose-dense CHOP-14 (cyclophosphamide, doxorubicin, vincristine, prednisone) ± rituximab
 - iv. MINE (mesna, ifosfamide, mitoxantrone, etoposide)
 - v. DHAP (dexamethasone, cisplatin, cytarabine)
 - vi. ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine (Ara-C))
 - vii. HyperCVAD ± rituximab (cyclophosphamide, vincristine, doxorubicin, dexamethasone ± rituximab)
 - viii. VAPEC-B (vincristine, doxorubicin, prednisolone, etoposide, cyclophosphamide, bleomycin)
- 11. Melanoma:
Dacarbazine-based combination with IL-2, interferon alpha (dacarbazine, cisplatin, vinblastine, IL-2, interferon alfa)
- 12. Multiple myeloma:
 - i. VTD-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide + bortezomib)
 - ii. DT-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide)
- 13. Ovarian Cancer:
 - i. Topotecan
 - ii. Docetaxel
- 14. Pancreatic Cancer:
FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin)
- 15. Soft Tissue Sarcoma:
 - i. MAID (mesna, doxorubicin, ifosfamide, dacarbazine)
 - ii. Doxorubicin
 - iii. Ifosfamide/doxorubicin

Reference number(s)
1930-A

16. Small Cell Lung Cancer:
 - i. Top (topotecan)
 - ii. CAV (cyclophosphamide, doxorubicin, vincristine)
17. Testicular cancer:
 - i. VeIP (vinblastine, ifosfamide, cisplatin)
 - ii. VIP (etoposide, ifosfamide, cisplatin)
 - iii. TIP (paclitaxel, ifosfamide, cisplatin)

*Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

B. APPENDIX B: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 10% to 19%*

1. Occult primary – adenocarcinoma:
Gemcitabine/docetaxel
2. Breast cancer:
 - i. Docetaxel
 - ii. CMF classic (cyclophosphamide, methotrexate, fluorouracil)
 - iii. CA (doxorubicin, cyclophosphamide) (60 mg/m²) (hospitalized)
 - iv. AC (doxorubicin, cyclophosphamide) + sequential docetaxel (taxane portion only)
 - v. AC + sequential docetaxel + trastuzumab
 - vi. A (doxorubicin) (75 mg/m²)
 - vii. AC (doxorubicin, cyclophosphamide)
 - viii. CapDoc (capecitabine, docetaxel)
 - ix. Paclitaxel every 21 days
3. Cervical Cancer:
 - i. Irinotecan
 - ii. Cisplatin/topotecan
 - iii. Paclitaxel/cisplatin
 - iv. Topotecan
4. Colorectal Cancer:
 - i. FL (fluorouracil, leucovorin)
 - ii. CPT-11 (irinotecan) (350 mg/m² q 3 wk)
 - iii. FOLFOX (fluorouracil, leucovorin, oxaliplatin)
5. Esophageal and Gastric Cancers:
 - i. Irinotecan/cisplatin
 - ii. Epirubicin/cisplatin/5-fluorouracil
 - iii. Epirubicin/cisplatin/capecitabine
6. Non-Hodgkin's lymphomas:
 - i. EPOCH-IT chemotherapy
 - ii. GDP (gemcitabine, dexamethasone, cisplatin/carboplatin)
 - iii. GDP (gemcitabine, dexamethasone, cisplatin/carboplatin) + rituximab
 - iv. FMR (fludarabine, mitoxantrone, rituximab)
 - v. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) including regimens with pegylated liposomal doxorubicin
 - vi. CHOP + rituximab (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) including regimens with pegylated liposomal doxorubicin
 - vii. CHP (cyclophosphamide, doxorubicin, prednisone) + brentuximab vedotin

Reference number(s)
1930-A

- viii. Bendamustine
- 7. Non-Small Cell Lung Cancer:
 - i. Cisplatin/paclitaxel
 - ii. Cisplatin/vinorelbine
 - iii. Cisplatin/docetaxel
 - iv. Cisplatin/etoposide
 - v. Carboplatin/paclitaxel
 - vi. Docetaxel
- 8. Ovarian cancer: Carboplatin/docetaxel
- 9. Prostate cancer: Cabazitaxel
- 10. Small Cell Lung Cancer: Etoposide/carboplatin
- 11. Testicular Cancer:
 - i. BEP (bleomycin, etoposide, cisplatin)
 - ii. Etoposide/cisplatin
- 12. Uterine sarcoma: Docetaxel

*Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

VI. REFERENCES

1. Neupogen [package insert]. Thousand Oaks, CA: Amgen Inc.; June 2018.
2. Nivestym [package insert]. Lake Forest, IL: Pfizer Inc.; July 2018.
3. Granix [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2019.
4. Zarxio [package insert]. Princeton, NJ: Sandoz Inc.; August 2019.
5. The NCCN Drugs & Biologics Compendium® © 2020 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed June 09, 2020.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. Accessed: June 02, 2020.
7. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at <https://www.micromedexsolutions.com>. (Accessed: 06/09/2020).
8. Lexicomp Online, AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; Accessed June 10, 2020.
9. Apro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. *Eur J Cancer*. 2011;47(1):8-32.
10. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015;33(28):3199-3212.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hairy Cell Leukemia. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf Accessed June 10, 2020.

Reference number(s)
1930-A

12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 3.2020.
https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf Accessed June 11, 2020.
13. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J Clin Oncol*. 2006;24(19):3187-3205.
14. NCCN hematopoietic growth factors. Short-term recommendations specific to issues with COVID-19 (SARS-CoV-2). National Comprehensive Cancer Network, Inc. Available at: https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf. Accessed June 02, 2020.